Home
overview
Announcing SMi's 5th Annual event... For the 5th year running, SMi will bring together key experts in the field to provide a platform for networking and discussion

A unique opportunity to learn from leading industry experts including:
· Dr Alejandro Aruffo, President, Abbott Bioresearch Center, Abbott
· Dr David Glover, Chief Medical Officer, Cambridge Antibody Technology
· Dr Vivian Albert, Vice President, Preclinical Research & Development, Human Genome Sciences
· Dr Joseph Bolen, Senior Vice President, Research & Drug Discovery, Millennium
· Dr Lutz Jermutus, Director, Antibody Engineering, Cambridge Antibody Technology
· Dr Eileen Elliott, Senior Director Immunology Biology, Pfizer
· Dr René Hoet, Director, Research & Technology, Dyax
· Dr Jane Osbourn, Vice President, Display Technology, Cambridge Antibody Technology
· Dr Leon Hooftman, Head, Clinical Development, Celltech
· Dr Simon Hufton, Director, Research & Technology, Dyax
· Dr Thomas von Rueden, Executive Vice President, Business Development & Chief Scientific Officer, MorphoSys

Hot topics to be covered at this event include:
· MARKET TRENDS: Look at key trends and predictions to 2008: How can you capitalise on the ‘fully human wave?’
· ANTIBODY TECHNOLOGIES: Identify the latest developments in ribosome, yeast and phage display technologies
· ONCOLOGY ANTIBODIES: Assess novel immunomodulatory approaches for cancer and hear about current projects from leading companies
· SYNTHETIC THERAPEUTIC ANTIBODIES: Discover the application of structure-based design to therapeutic antibody development
· CASE STUDIES: Meet leaders in the field and learn from their mixed experiences in oncology and other therapeutic areas including inflammatory and infectious diseases

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Lutz Jermutus

Dr Lutz Jermutus, Director, Antibody Engineering, Cambridge Antibody Technology

9:10 THE THERAPEUTIC ANTIBODIES MARKET

Dr Alex Pavlou

Dr Alex Pavlou, Head, Biotechnology Analysis / Member, Datamonitor / European Federation of Biotech

  • The market size growth and key trends to 2008 (in terms of technological platform: human, humanised, chimeric etc.)
  • Key therapeutic trends: key indications to 2008 and revenue performance
  • Leading brands: the size of the new wave of antibody blockbusters
  • The evolution of the Ab biotech business models and key industry challenges
  • 9:40 ANTIBODY DISCOVERY: RIBOSOME DISPLAY TECHNOLOGIES

    Dr Jane Osbourn

    Dr Jane Osbourn, Vice President, Display Technology, Cambridge Antibody Technology

  • Overview of the ribosome display process
  • Advantages of ribosome display over other display systems
  • Application of ribosome display to potency engineering
  • Other applications of ribosome display
  • 10:20 PROTEIN ENGINEERING BY YEAST SURFACE DISPLAY

    Dr K Dane Wittrup

    Dr K Dane Wittrup, JR Mares Professor of Chemical Engineering & Bioengineering, Massachusetts Institute of Technology

  • Novel comprehensive mutagenesis strategies integrating recombination and point mutation
  • Intrabody development by yeast surface display
  • Expression maturation of difficult antigens
  • Fibronectin-domain and single-domain antibody display
  • Shotgun epitope mapping by yeast surface display
  • 11:00 Morning Coffee

    11:20 COMBINATORIAL YEAST MATING TECHNOLOGY

    Dr Simon Hufton

    Dr Simon Hufton, Director, Research & Technology, Dyax

  • Affinity maturation of Fab antibodies by yeast display
  • Development of novel technology for the rapid construction of Fab antibody repertoires using combinatorial yeast mating
  • Facilitates rapid and iterative chain shuffling of antibody vs genes
  • Rapid construction of large naïve yeast displayed fab antibody libraries
  • 12:00 THE LATEST DEVELOPMENTS IN ANTIBODY PHAGE DISPLAY TECHNOLOGY

    Dr René Hoet

    Dr René Hoet, Director, Research & Technology, Dyax

  • Construction and use of Dyax novel phage and phagemid human antibody libraries
  • Novel antibody diversity combining careful synthetic design with natural human donor diversity
  • Automated controlled phage display selection methods on purified protein targets, peptides and cells
  • High-throughput screening methods to identify antibody leads
  • Examples of therapeutic antibody leads from Dyax antibody pipeline
  • 12:40 Networking Lunch

    14:00 FROM TARGET IDENTIFICATION AND VALIDATION TO THERAPEUTIC ANTIBODY LEADS

    Kristian Jensen

    Kristian Jensen, Group Leader, Xerion Pharmaceuticals

  • Successful selection of phage display libraries against cell surfaces
  • Efficient target validation using chromophore-assisted laser inactivation (CALI) technology
  • Combination of phage display, CALI and mass spectrometry produces a technology platform for the systematic identification and functional validation of novel drug targets
  • Examples from the validation, identification and therapeutic antibody lead generation against cancer and angiogenesis targets
  • 14:40 SYNTHETIC THERAPEUTIC ANTIBODIES

    Frederic Fellouse

    Frederic Fellouse, Senior Research Associate, Genentech

  • High affinity antibodies derived from synthetic repertoires
  • Structural and functional analysis of antigen recognition
  • Highly optimised synthetic libraries with limited amino acid diversities
  • Implications for antibody engineering and therapeutic applications
  • 15:20 Afternoon Tea

    15:40 SEARCHING FOR NOVEL TARGET MOLECULES ON TUMOUR CELLS

    Dr John de Kruif

    Dr John de Kruif, Director, Antibody Technology, Crucell

  • Selections on tumour samples
  • Downstream processing isolated clones
  • Target identification using expression cloning and MS
  • Characterisation of novel molecules
  • Technology evaluation
  • 16:20 A HUMAN CTLA4-SPECIFIC ANTIBODY

    Dr Eileen Elliott

    Dr Eileen Elliott, Senior Director, Immunology Biology, Pfizer

  • Discovery
  • >In vitro characterization
  • Biomarkers of activity
  • Clinical status
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Alex Pavlou

    Dr Alex Pavlou, Head, Biotechnology Analysis / Member, Datamonitor / European Federation of Biotech

    9:10 MLN 2704 – A TOXIN-CONJUGATED HUMANISED MAB DIRECTED AGAINST THE PROSTATE SPECIFIC MEMBRANE ANTIGEN FOR TREATMENT OF ANDROGEN-INDEPENDENT PROSTATE CANCER

    Dr Joseph Bolen

    Dr Joseph Bolen, Senior Vice President, Research & Drug Discovery, Millennium

  • Target identification
  • Target validation
  • MLN 2704 development
  • Status of MLN 2704 clinical trials
  • 9:40 AGONISTIC APOPTOSIS-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER

    Dr Vivian Albert

    Dr Vivian Albert, Vice President, Preclinical Research & Development, Human Genome Sciences

    10:20 CHALLENGES IN THE CLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY FOR BREAST CANCER

    Dr Tamas Suto

    Dr Tamas Suto, Clinical Scientist, F Hoffmann-La Roche

  • Herceptin®: past and future
  • Herceptin® clinical development
  • Challenges: cardiac events, pharmacokinetics
  • Linking molecular diagnostics to therapy
  • Integrated approach to breast cancer
  • 11:00 Morning Coffee

    11:20 SUPERAGONISTIC CD28-SPECIFIC ANTIBODIES

    Dr Thomas Hanke

    Dr Thomas Hanke, Chief Scientific Officer, TeGenero

  • Company strategy
  • Technological concept
  • Immunoreconstitution and immunosuppression
  • Therapeutic potential of superagonistic anti-CD28 antibodies
  • 12:00 HUMAN ANTIBODY DEVELOPMENT: HUMIRA - A CASE STUDY

    Dr Alejandro Aruffo

    Dr Alejandro Aruffo, President, Abbott Bioresearch Center

  • Identification of human anti-TNF mAb
  • Affinity maturation of human anti-TNF mAb
  • Overview of HUMIRA clinical development
  • 12:40 Networking Lunch

    14:00 CLINICAL DEVELOPMENT OF PEGYLATED ANTIBODY FAB’ FRAGMENTS

    Dr Leon Hooftman

    Dr Leon Hooftman, Head, Clinical Development, Celltech

  • Humanised PEG conjugate
  • Pharmacokinetics
  • CDP 870, anti-TNF
  • CDP 484, anti-ILbeta
  • Disease indications
  • 14:40 DEVELOPING MONOCLONAL HUMAN ANTI-TOXIN THERAPIES FOR ANTHRAX

    Dr Martha Wild

    Dr Martha Wild, Lead, Principal Scientist, Anthrax Programme, Alexion Antibody Technologies

  • Source for library construction
  • Anti-toxin attributes from Fab to mAb
  • Defining mechanism of action
  • Desired qualities for anti-toxin therapy
  • Production considerations and issues in building an emergency stockpile
  • 15:20 Afternoon Tea

    15:40 TRABIO

    Dr David Glover

    Dr David Glover, Chief Medical Officer, Cambridge Antibody Technology

  • The concept: prevention of excessive scaring after eye surgery
  • The molecular target: transforming growth factor beta2
  • The progress: from concept to phase III clinical trials
  • The learning points: for the company and the programme
  • 16:20 TREATING INFLAMMATORY DISEASES

    Dr Jutta Haunschild

    Dr Jutta Haunschild, Director, Research & Development, MorphoSys

  • Validation of ICAM1 as therapeutic target
  • First fully human antibodies targeting ICAM1
  • In vitro profiling
  • In vivo efficacy in psoriasis animal models
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.